Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach

(2012) Claudio Gasperini et al.   Drug Design Development and Therapy

Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy

(2012) Douglas R. Jeffery   Therapeutic Advances in Chronic Disease

Oral treatment for multiple sclerosis

(2011) Joep Killestein et al.   LANCET NEUROLOGY

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

(2011) M Calabrese et al.   Multiple Sclerosis Journal

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination

(2011) Volker Limmroth et al.   Therapeutic Advances in Neurological Disorders

Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis

(2010) Nicola De Stefano et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY